ArticleJCO global oncology2022
HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana.
Article in JCO global oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma.Oncology research · 2026Review
- Hodgkin lymphoma treatment patterns and outcome disparities in low- and middle-income countries.Blood global hematology · 2025Article
- Early-stage Hodgkin lymphoma in Cape Town, South Africa: prognostic risk factors at diagnosis and treatment outcomes.BMC cancer · 2025Article
- Quality of life among non-metastatic breast cancer survivors in Botswana.Journal of cancer survivorship : research and practice · 2025Article
- Advanced aggressive clinical features may be associated with immune dysfunction in patients with HIV-positive Hodgkin lymphoma in the cART era: a multicenter study from China.Frontiers in immunology · 2025Article
- Retrospective analysis of HIV-associated lymphomas: insights from a single Romanian center over 15 years.Frontiers in oncology · 2025Article
- Access to and Utilization of Endocrine Therapy Among Breast Cancer Survivors in Botswana.JCO global oncology · 2024Article
- Hodgkin lymphoma: the role of EBV plasma viral load testing in an HIV-endemic setting.Clinical and experimental medicine · 2024Article
- Real-world treatment outcomes for Hodgkin lymphoma in South Africa: a prospective observational study.Infectious agents and cancer · 2024Article
- A comparison of clinical profile and treatment outcome of Hodgkin's Lymphoma in Tanzania according to HIV status during the HAART era.BMC cancer · 2024Article
- Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study.EClinicalMedicine · 2024Article
- State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI.International journal of cancer · 2024Review
- Outcomes of patients with haematological malignancies and febrile neutropenia at the Universitas Academic Hospital multidisciplinary intensive care unit, Free State Province, South Africa.African journal of thoracic and critical care medicine · 2023Article
- CD4Open life sciences · 2023Article
- Use of granulocyte colony-stimulating factor in patients with chemotherapy-induced neutropaenia.Health SA = SA Gesondheid · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 2 countries.
Funding
Abstract
purposePeople living with HIV (PLWH) experience increased risk of Hodgkin lymphoma (HL) despite effective initiation of antiretroviral therapy (ART). In high-income countries, outcomes following HIV HL have been reported to be non-differential, or inferior for PLWH. We sought to assess the effect of HIV on HL survival in Botswana, an African country with a generalized HIV epidemic and high ART coverage, to describe a context more reflective of global HIV populations. PATIENTS AND
methodsIn the Thabatse Cancer Cohort, consenting participants initiating treatment for HL at one of four cancer centers in Botswana were enrolled from 2010 to 2020. Patients were followed quarterly for up to 5 years. The impact of HIV on survival following treatment initiation was assessed using an inverse probability-weighted Cox marginal structural model adjusted for age, performance status, and disease stage.
resultsSeventy-eight new HL cases were enrolled, 47 (60%) were PLWH and 31 (40%) were HIV-uninfected. Baseline characteristics were similar between groups. The majority (61%) of patients presented with regional disease (stage I or II) with no statistically significant difference by HIV status (
conclusionIn this cohort of patients treated for HL in Botswana, survival in PLWH (87% on long-standing ART) was at least as good as in individuals without HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.